{"id":20,"date":"2025-03-25T05:20:00","date_gmt":"2025-03-25T05:20:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=20"},"modified":"2025-08-28T10:30:04","modified_gmt":"2025-08-28T10:30:04","slug":"approved-505b2-drug-development-by-china-companies","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/20.html","title":{"rendered":"[China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1\/GIP\/glucagon triple receptor agonist"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-03-24 (March 24, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: UBT251<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: United Laboratories (The United Laboratories International Holdings Limited (TUL)  and the wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology),\u00a0China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Novo Nordisk\uff08Novo Nordisk A\/S\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: GLP-1\/GIP\/GCG triple receptor agonist<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\uff08\u00a0glucagon-like peptide-1\uff0cglucose-dependent insulinotropic polypeptide\uff0c glucagon\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Small \u00a0Molecule\uff0clong-acting synthetic peptide <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage:  Early-stage clinical development\u00a0, phase 1b, phase 2 trial in China\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Deal Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of\u00a0 $200 million;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Milestone payments up to \u00a0$1.8 billion;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Total up to $2 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Additional royalties based on net sales in the licensed territories.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1\/GIP\/glucagon triple receptor agonist<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=915958\">https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=915958<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-03-24 (March 24, 2025) Asset Name: UBT251 Licensor: United Laboratories (The United Laboratories International &hellip; <a title=\"[China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1\/GIP\/glucagon triple receptor agonist\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/20.html\"><span class=\"screen-reader-text\">[China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1\/GIP\/glucagon triple receptor agonist<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-20","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/20","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=20"}],"version-history":[{"count":3,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/20\/revisions"}],"predecessor-version":[{"id":81,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/20\/revisions\/81"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=20"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=20"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=20"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}